One-stop Services from Drug Discovery through Post-marketing
First written in FY2024. 2 of 4 entries say "Advanced", first in 2026-06-02. Latest entry: FY2026.
The whole theme swung hardest in 2020: 1 of 7 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「For emerging biotechnology companies and pharmaceutical companies in Japan and overseas that are considering entering the Japanese, European, North American and Asian markets, our group provides drug discovery support services including pharmaceutical market analysis and development strategy planning, regulatory filings and consultations, preparation of clinical trial protocols and application-related documents, applications for regulatory approval, and partnering support such as co-development and licensing. When clients proceed to clinical development, we provide one-stop services including our core monitoring operations, medical writing, data management and statistical analysis, and safety information management.」
The specific scope of one-stop services, including upstream and downstream processes from drug discovery support through clinical development, regulatory applications, post-marketing clinical research and publication preparation, has been expanded in the description. - FY2024First statedAnnual report
「Through these businesses, we provide global one-stop services ranging from drug discovery support for new drug development and clinical development to post-marketing clinical trials and clinical research, covering post-approval lifecycle management.」
A service concept integrating drug discovery support, clinical development, and post-marketing clinical trials and clinical research to provide global support throughout the pharmaceutical lifecycle is explicitly presented as a standalone theme.